NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis $8.59 +0.45 (+5.53%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Indivior Stock (NASDAQ:INDV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Indivior alerts:Sign Up Key Stats Today's Range$8.29▼$8.7650-Day Range$7.46▼$12.7452-Week Range$7.33▼$23.22Volume1.19 million shsAverage Volume436,881 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company OverviewIndivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Indivior Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks80th Percentile Overall ScoreINDV MarketRank™: Indivior scored higher than 80% of companies evaluated by MarketBeat, and ranked 243rd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 2 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth20.00% Earnings GrowthEarnings for Indivior are expected to grow by 20.00% in the coming year, from $1.70 to $2.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is -8.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is -8.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndivior has a P/B Ratio of 23.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Indivior's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently decreased by 15.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.62% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently decreased by 15.69%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.32 News SentimentIndivior has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Indivior this week, compared to 5 articles on an average week.Search Interest6 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Indivior to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INDV Stock News HeadlinesTwo Seas Capital LP Increases Stake in Indivior PLCOctober 17 at 7:29 PM | finance.yahoo.comPiper Sandler Reaffirms "Overweight" Rating for Indivior (NASDAQ:INDV)October 15 at 1:57 AM | americanbankingnews.comThis man predicted today’s most valuable companies more than a decade ago.How could it be that one analyst called the rise of Apple, Microsoft, Nvidia, and many of today’s best performing stocks more than a decade ago? Some might say it was luck… Others will say he was in the right place at the right time. But looking back, this analyst has made some incredible calls over his career… In fact, right now, he’s the #1 ranked stock picker in North America… To earn that title he’s beat out more than 16,000 stock market professionals. So how does one man accomplish all that? If you were to ask him, he’d give the credit to his stock rating system…. A system that has a history of predicting which stocks could soon rise by 100% or more…October 17, 2024 | DTI (Ad)Indivior (NASDAQ:INDV) Sees Strong Trading Volume - Should You Buy?October 13, 2024 | americanbankingnews.comIndivior price target lowered to $16 from $20 at Craig-HallumOctober 12, 2024 | finance.yahoo.comIndivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...October 11, 2024 | finance.yahoo.comIndivior falls as headwinds to Sublocade prompt another guidance cutOctober 10, 2024 | msn.comIndivior (NASDAQ:INDV) Shares Gap Down - Time to Sell?October 10, 2024 | americanbankingnews.comSee More Headlines INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at $15.27 at the beginning of the year. Since then, INDV shares have decreased by 43.7% and is now trading at $8.59. View the best growth stocks for 2024 here. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) released its earnings results on Thursday, July, 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.04. The business had revenue of $299 million for the quarter, compared to analyst estimates of $285.90 million. Indivior had a negative net margin of 12.29% and a negative trailing twelve-month return on equity of 654.82%. Who are Indivior's major shareholders? Top institutional shareholders of Indivior include Artemis Investment Management LLP (0.09%). How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings7/25/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDV CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,164Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$16.00 Low Stock Price Target$15.00 Potential Upside/Downside+80.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E RatioN/A Forward P/E Ratio5.05 P/E GrowthN/ANet Income$2 million Net Margins-12.29% Pretax Margin-16.65% Return on Equity-654.82% Return on Assets13.01% Debt Debt-to-Equity Ratio23.50 Current Ratio0.85 Quick Ratio0.68 Sales & Book Value Annual Sales$1.15 billion Price / Sales1.03 Cash Flow$1.66 per share Price / Cash Flow5.19 Book Value$0.37 per share Price / Book23.22Miscellaneous Outstanding Shares137,879,000Free FloatN/AMarket Cap$1.18 billion OptionableNot Optionable Beta0.68 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:INDV) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.